Attention is being focused on a side effect of Biogen’s Alzheimer’s drug, Aduhelm (aducanumab). Even before its controversial approval on June 7, there were cases of amyloid-related imaging abnormalities (ARIA‑E), or cerebral edema, observed in the trials. [Read more…] about Amyloid-related imaging abnormalities (ARIA) found in approximately 40% of patients taking “Alzheimer’s drug” Aduhelm
Brain/ Mental Health
The U.S. Food and Drug Administration has approved a clinical trial using a neuroimaging helmet made by Los Angeles-based Kernel to track what happens in the brain when a human takes a psychedelic dose of ketamine. [Read more…] about FDA-approved, Cybin-sponsored clinicial trial to measure ketamine’s impact on the brain via Kernel Flow neuroimaging helmet
Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found a ready market in pharmaceutical companies interested in assessing how their experimental brain therapies are working. Now Beacon Biosignals has something else: $27 million in financing. [Read more…] about Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform
Former U.S. Ambassador to the United Nations Nikki Haley suggested in an interview on Thursday that leaders in the government who are of an advanced age should undergo a “cognitive test.” [Read more…] about Revisiting the question: Should older politicians, and other leaders, undergo cognitive testing?
The Digital Therapeutics Alliance Welcomes Decision by the CPT® Editorial Panel to Clarify Reporting of Remote Cognitive Behavioral Therapy Monitoring Services (press release):
As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance (DTA) welcomes the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel’s recent decision to clarify reporting of remote cognitive behavioral therapy (CBT) monitoring services. The changes to the CPT code set reflect the growing recognition that digital therapeutics (DTx) are an effective treatment for patients with mental health conditions and physicians should ultimately be reimbursed for their time spent prescribing, monitoring, and supplying online CBT technologies. [Read more…] about The American Medical Association’s (AMA) to ease access to remote Cognitive Behavioral Therapy Monitoring
Another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place, thanks to a third multimillion-dollar investment in Click Therapeutics in barely a year. [Read more…] about Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more